港股创新药概念股走强，相关ETF涨约3%

Group 1 - The core viewpoint is that Hong Kong's innovative pharmaceutical stocks have strengthened, with notable increases in companies such as 3SBio, which rose over 7%, and others like Innovent Biologics, Kelun-Botai, and Rongchang Biologics, which increased by over 4% [1] - The Hong Kong innovative pharmaceutical-related ETFs have also seen a rise of approximately 3% [1] - Analysts believe that China's innovative pharmaceutical industry is integrating strongly into the global pharmaceutical innovation system, transitioning from a focus on generic drugs to a significant increase in the share of global innovative drug business collaborations [2] Group 2 - The article provides specific data on various Hong Kong innovative pharmaceutical ETFs, including their current prices, changes, and percentage increases, such as the Hong Kong Innovative Pharmaceutical ETF T+0, which is priced at 0.833 with a 3.35% increase [2] - The transition of China's innovative pharmaceutical industry is characterized by a shift from "following" and "running alongside" to "leading" in certain areas, supported by policy, clinical breakthroughs, and capital assistance [2]